Market closed
CEL-SCI/$CVM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CEL-SCI
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Ticker
$CVM
Sector
Trading on
AMEX
Industry
Biotechnology
Headquarters
Employees
44
Website
CEL-SCI Metrics
BasicAdvanced
$20M
-
-$0.48
0.67
-
Price and volume
Market cap
$20M
Beta
0.67
52-week high
$2.39
52-week low
$0.18
Average daily volume
1.3M
Financial strength
Current ratio
1.069
Quick ratio
0.843
Long term debt to equity
77.689
Total debt to equity
98.033
Interest coverage (TTM)
-37.27%
Management effectiveness
Return on assets (TTM)
-61.48%
Return on equity (TTM)
-233.26%
Valuation
Price to book
1.58
Price to tangible book (TTM)
1.61
Price to free cash flow (TTM)
-0.777
Growth
Earnings per share change (TTM)
-29.35%
3-year earnings per share growth (CAGR)
-19.51%
What the Analysts think about CEL-SCI
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for CEL-SCI stock.
CEL-SCI Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CEL-SCI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CEL-SCI News
AllArticlesVideos
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
Business Wire·2 weeks ago
New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
Business Wire·1 month ago
CEL-SCI Announces Pricing of $2.5 Million Offering
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for CEL-SCI stock?
CEL-SCI (CVM) has a market cap of $20M as of May 09, 2025.
What is the P/E ratio for CEL-SCI stock?
The price to earnings (P/E) ratio for CEL-SCI (CVM) stock is 0 as of May 09, 2025.
Does CEL-SCI stock pay dividends?
No, CEL-SCI (CVM) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next CEL-SCI dividend payment date?
CEL-SCI (CVM) stock does not pay dividends to its shareholders.
What is the beta indicator for CEL-SCI?
CEL-SCI (CVM) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.